Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
0.6844 x 1 0.8324 x 2
Pre-market by (Cboe BZX)
0.7529 +0.0729 (+10.72%) 04/04/25 [NASDAQ]
0.6844 x 1 0.8324 x 2
Pre-market 0.7529 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.6611
Day High
0.7647
Open 0.6900
Previous Close 0.6800 0.6800
Volume 3,608,200 3,608,200
Avg Vol 1,804,055 1,804,055
Stochastic %K 14.95% 14.95%
Weighted Alpha -89.61 -89.61
5-Day Change -0.0964 (-11.35%) -0.0964 (-11.35%)
52-Week Range 0.6611 - 7.1400 0.6611 - 7.1400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,280
  • Shares Outstanding, K 114,597
  • Annual Sales, $ 13,630 K
  • Annual Income, $ -186,260 K
  • EBIT $ -196 M
  • EBITDA $ -186 M
  • 60-Month Beta 2.41
  • Price/Sales 5.72
  • Price/Cash Flow N/A
  • Price/Book 0.24
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.51
  • Most Recent Earnings $-0.31 on 03/05/25
  • Next Earnings Date 05/08/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 238.06% ( +16.48%)
  • Historical Volatility 93.36%
  • IV Percentile 83%
  • IV Rank 42.74%
  • IV High 541.64% on 12/12/24
  • IV Low 11.45% on 09/16/24
  • Put/Call Vol Ratio 31.00
  • Today's Volume 256
  • Volume Avg (30-Day) 139
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 5,581
  • Open Int (30-Day) 4,578

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.40
  • Number of Estimates 6
  • High Estimate -0.31
  • Low Estimate -0.45
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +14.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6611 +13.89%
on 04/04/25
Period Open: 0.9500
1.0600 -28.97%
on 03/06/25
-0.1971 (-20.75%)
since 03/04/25
3-Month
0.6611 +13.89%
on 04/04/25
Period Open: 1.8000
1.9900 -62.17%
on 01/06/25
-1.0471 (-58.17%)
since 01/03/25
52-Week
0.6611 +13.89%
on 04/04/25
Period Open: 6.9700
7.1400 -89.46%
on 04/05/24
-6.2171 (-89.20%)
since 04/04/24

Most Recent Stories

More News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 0.7529 (+10.72%)
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never been more...

ALLO : 1.4400 (+4.35%)
ONCY : 0.4952 (-3.28%)
TARA : 3.90 (-9.83%)
YMAB : 4.54 (-2.58%)
FATE : 0.7529 (+10.72%)
ONC.TO : 0.70 (-1.41%)
Fate Therapeutics: Q4 Earnings Snapshot

Fate Therapeutics: Q4 Earnings Snapshot

FATE : 0.7529 (+10.72%)
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

FATE : 0.7529 (+10.72%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FATE : 0.7529 (+10.72%)
Fate Therapeutics to Present at Upcoming Investor Conferences

FATE : 0.7529 (+10.72%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 0.7529 (+10.72%)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE : 0.7529 (+10.72%)
Fate Therapeutics Reports Positive Phase 1 Results for FT819 in Lupus Treatment with Favorable Safety Profile and Initiates Dose Expansion

Fate Therapeutics reports positive results from FT819 study in lupus, showing effective B-cell depletion and favorable safety outcomes.Quiver AI SummaryFate Therapeutics, Inc. announced promising results...

FATE : 0.7529 (+10.72%)
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

FATE : 0.7529 (+10.72%)

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 0.8950
2nd Resistance Point 0.8298
1st Resistance Point 0.7914
Last Price 0.7529
1st Support Level 0.6878
2nd Support Level 0.6226
3rd Support Level 0.5842

See More

52-Week High 7.1400
Fibonacci 61.8% 4.6651
Fibonacci 50% 3.9005
Fibonacci 38.2% 3.1360
Last Price 0.7529
52-Week Low 0.6611

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades